IL188181A - Monohydrate of 2- (6-methyl-pyridine-2-yl) -3-) 6-amido-quinoline-4-yl) -6,5-dihydro-h4-pyrrolo [2,1- b] pyrazole as an anti-drug Cancerous and pharmaceuticals containing it - Google Patents

Monohydrate of 2- (6-methyl-pyridine-2-yl) -3-) 6-amido-quinoline-4-yl) -6,5-dihydro-h4-pyrrolo [2,1- b] pyrazole as an anti-drug Cancerous and pharmaceuticals containing it

Info

Publication number
IL188181A
IL188181A IL188181A IL18818107A IL188181A IL 188181 A IL188181 A IL 188181A IL 188181 A IL188181 A IL 188181A IL 18818107 A IL18818107 A IL 18818107A IL 188181 A IL188181 A IL 188181A
Authority
IL
Israel
Prior art keywords
methyl
quinolin
pyridin
pyrrolo
dihydro
Prior art date
Application number
IL188181A
Other languages
English (en)
Hebrew (he)
Other versions
IL188181A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL188181A0 publication Critical patent/IL188181A0/en
Publication of IL188181A publication Critical patent/IL188181A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL188181A 2005-07-22 2007-12-17 Monohydrate of 2- (6-methyl-pyridine-2-yl) -3-) 6-amido-quinoline-4-yl) -6,5-dihydro-h4-pyrrolo [2,1- b] pyrazole as an anti-drug Cancerous and pharmaceuticals containing it IL188181A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70164105P 2005-07-22 2005-07-22
PCT/US2006/025377 WO2007018818A1 (en) 2005-07-22 2006-06-29 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor

Publications (2)

Publication Number Publication Date
IL188181A0 IL188181A0 (en) 2008-03-20
IL188181A true IL188181A (en) 2014-05-28

Family

ID=37450942

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188181A IL188181A (en) 2005-07-22 2007-12-17 Monohydrate of 2- (6-methyl-pyridine-2-yl) -3-) 6-amido-quinoline-4-yl) -6,5-dihydro-h4-pyrrolo [2,1- b] pyrazole as an anti-drug Cancerous and pharmaceuticals containing it

Country Status (16)

Country Link
US (1) US7872020B2 (cg-RX-API-DMAC7.html)
EP (1) EP1910370B1 (cg-RX-API-DMAC7.html)
JP (1) JP5242391B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613639A2 (cg-RX-API-DMAC7.html)
CA (1) CA2616196C (cg-RX-API-DMAC7.html)
DK (1) DK1910370T3 (cg-RX-API-DMAC7.html)
ES (1) ES2542425T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150474T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025209T2 (cg-RX-API-DMAC7.html)
IL (1) IL188181A (cg-RX-API-DMAC7.html)
MX (1) MX2008001020A (cg-RX-API-DMAC7.html)
PL (1) PL1910370T3 (cg-RX-API-DMAC7.html)
PT (1) PT1910370E (cg-RX-API-DMAC7.html)
RS (1) RS53999B1 (cg-RX-API-DMAC7.html)
SI (1) SI1910370T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007018818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
RU2612958C2 (ru) 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
EP2917365B1 (en) 2012-11-12 2020-03-11 Institució Catalana de Recerca i Estudis Avançats Methods and kits for the prognosis of colorectal cancer
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2018165979A1 (zh) * 2017-03-17 2018-09-20 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1397364T1 (sl) * 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
EP1567528A1 (en) * 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles

Also Published As

Publication number Publication date
RS53999B1 (sr) 2015-10-30
BRPI0613639A2 (pt) 2012-02-22
JP2009502780A (ja) 2009-01-29
CA2616196A1 (en) 2007-02-15
EP1910370B1 (en) 2015-04-22
HUE025209T2 (en) 2016-03-29
ES2542425T3 (es) 2015-08-05
MX2008001020A (es) 2008-03-25
PT1910370E (pt) 2015-06-30
EP1910370A1 (en) 2008-04-16
SI1910370T1 (sl) 2015-06-30
CA2616196C (en) 2012-08-21
IL188181A0 (en) 2008-03-20
US7872020B2 (en) 2011-01-18
HRP20150474T1 (xx) 2015-06-05
DK1910370T3 (en) 2015-06-08
WO2007018818A1 (en) 2007-02-15
JP5242391B2 (ja) 2013-07-24
US20100120854A1 (en) 2010-05-13
PL1910370T3 (pl) 2015-09-30

Similar Documents

Publication Publication Date Title
EP1910370B1 (en) A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
DK3037424T3 (en) NEW QUINOLIN-SUBSTITUTED COMPOUND
EP3409667B1 (en) Amide compounds for the treatment of hiv infections
US10954252B1 (en) Inhibitors of human immunodeficiency virus replication
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
EP2985277A1 (en) Dipyrromethene crystal and method for manufacturing same
JP2015180679A (ja) ナトリウム4−{[9−クロロ−7−(2−フルオロ−6−メトキシフェニル)−5H−ピリミド[5,4−d][2]ベンゾアゼピン−2−イル]アミノ}−2−メトキシベンゾエートの結晶形
JP2015520186A (ja) 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物
SK9622000A3 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
HUE029343T2 (en) Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof
EP3892621A1 (en) Haloallylamine compounds and application thereof
JP2016517845A (ja) PERK阻害剤としての新規なN(2,3−ジヒドロ−1H−ピロロ[2,3−b]ピリジン−5−イル)−4−キナゾリンアミン誘導体およびN−(2,3−ジヒドロ−1H−インドール−5−イル)−4−キナゾリンアミン誘導体
EP3434674B1 (en) ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer
EP4332101A1 (en) Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof
EP3854793A1 (en) Aromatic heterocyclic compound with kinase inhibitory activity
WO2014020531A1 (en) Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors
TW202329952A (zh) 克拉生坦(clazosentan)二鈉鹽之製備方法
WO2002094832A1 (en) New benzylaminopyrimidines
HK40053245A (en) Haloallylamine compounds and application thereof
HK1241358A1 (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
AU2002338927A1 (en) New benzylaminopyrimidines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees